News & Updates

Treatment with rivaroxaban for 3 months leads to a safe and successful reduction of recurrent venous thromboembolism (VTE) risk compared to treatment for 6 weeks in patients with isolated distal deep vein thrombosis (DVT), a study has shown.

Close blood pressure (BP) monitoring and more intensive and combined antihypertensive therapy are needed when there is a high prevalence of uncontrolled arterial hypertension (AH) despite the successful coarctation of the aorta (CoA) correction and use of relatively low doses of antihypertensive drugs, suggests a recent study.

In the phase III part of the PANAMO trial, the anti-C5a monoclonal antibody vilobelimab, when added to standard of care (SoC), improved survival in COVID-19 patients who required invasive mechanical ventilation (IMV).

A recent study has demonstrated the safety and efficacy of bulevirtide (BLV) monotherapy for 48 weeks in difficult-to-treat patients with hepatitis delta virus (HDV)-related compensated cirrhosis and clinically significant portal hypertension (CSPH).

The use of alprazolam leads to rapid termination of seizures in patients with focal and/or generalized epilepsy treated in an inpatient setting, according to the results of the phase II study ENGAGE-E-001.

Although the incidence of myocarditis or pericarditis following mRNA COVID-19 vaccination is low, a two- to threefold higher likelihood is seen among individuals who received mRNA-1273 compared to BNT162b2 vaccine, reveals a study.